



Hôpital général juif
Jewish General Hospital



McGill

Institut Lady Davis de recherches médicales | Lady Davis Institute for Medical Research
VERY DISTINGUISHED LECTURE SERIES



Jacques Galipeau, M.D.

Don and Marilyn Anderson Professor in Oncology

Assistant Dean for Therapeutics Discovery and Development

Director, Program for Advanced Cell Therapy

University of Wisconsin in Madison

Mesenchymal Stromal Cell Suppression of Immune Response: From Discovery to Design of Cell Therapy Studies

Tuesday, January 17, 2017

12:00 pm – 1:00 pm

LDI BLOOMFIELD LECTURE HALL, F-4

3999, Chemin de la Côte-Ste-Catherine (corner of Legaré)

Montréal, Québec H3T 1E2 CANADA (Conférence en anglais seulement)

After completing his medical degree, Jacques Galipeau, M.D. FRCP(C), received further training from the Tufts-affiliated New England Medical Center and subsequently at St-Jude Children's research hospital. Starting in 1997, Dr. Galipeau served as faculty at McGill University before joining Emory University in 2009 as a Professor of Hematology & Oncology and the Director of the Emory Personalized Immunotherapy Center. Since September 2016, he has been a Professor of Oncology at the University of Wisconsin in Madison (UoW). Here, he serves as the director of the UoW Advanced Cell Therapy Program whose mission is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy

first-in-human clinical trials of cell therapy innovations. Dr. Galipeau has developed an NIH-funded research program in the study and use of mesenchymal stromal cells as an immunotherapy of catastrophic illnesses including cancer and immune disease. He is an internationally recognized expert in the translational development of cell therapies and the sponsor of a series of clinical trials examining the use of autologous marrow-derived mesenchymal stromal cells for immune disorders, including Crohn's disease and graft vs host disease. He has also developed the field of fusion engineered cytokines known as fusokines, as a novel pharmaceutical means of treating immune disorders and cancer.

Host: Dr. Rod McInnes ext 5252/ e-mail: rod.mcinnis@mcgill.ca